Article
Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment.
British journal of cancer - 1 Aug 2018
de Langen Adrianus J, Jebbink M, Hashemi Sayed M S, Kuiper Justine L, de Bruin-Visser J, Monkhorst Kim, Thunnissen Erik, Smit Egbert F
Abstract excerpt
BACKGROUND: HER2 expression and amplification are observed in ~15% of tumour biopsies from patients with a sensitising EGFR mutation who develop EGFR TKI resistance. It is unknown whether HER2 targeting in this setting can result in tumour responses. METHODS: A single arm phase II study was performed to study the safety and efficacy of trastuzumab and paclitaxel treatment in patients with a sensitising EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.